BioSpace News Archive

Icosavax, Inc. today announced the initiation of a Phase 1 clinical trial of IVX-A12, a combination bivalent RSV and hMPV VLP vaccine candidate, in older adults.

James R. “Jim” Andrews , MD, Chairman and CEO of Andrews Medicine of Pensacola, Florida , and David G. Eller , Chairman and CEO of Celltex Therapeutics Corporation of Houston, Texas, announced today that together they will form a new biotechnology company to bridge the divide between stem cell research and the current treatment of athletic injuries.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2022 financial and operating results on Thursday, November 3, 2022, before the U.S. financial markets open.

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced today that the U.S. Food and Drug Administration (FDA) has approved its manufacturing operations in Costa Rica for the production of its proprietary spinal cord stimulation systems for the treatment of chronic pain, including its HFX product platform.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2022 results after the financial markets close on Wednesday, November 2, 2022.

GT Biopharma, Inc. today announced that its 2022 Special Shareholders Meeting has been adjourned to October 10, 2022 at 11 a.m. PST due to lack of quorum for its previously scheduled meeting.

Healthpeak Properties, Inc. (NYSE: PEAK) is scheduled to report its third quarter financial results after the close of trading on the New York Stock Exchange on Tuesday, November 1, 2022.

Envista Holdings Corporation (NYSE: NVST) (“Envista”) will report financial results for its third quarter 2022 on Thursday, November 3, 2022.

Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that management will participate in the following investor conferences during October 2022.

Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced the launch of an underwritten public offering of 6,000,000 shares of common stock pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (“SEC”).